Switching to deltoid intramuscular injections maintains therapeutic trough concentrations of rilpivirine and cabotegravir in people with HIV

Antimicrob Agents Chemother. 2024 May 2;68(5):e0017524. doi: 10.1128/aac.00175-24. Epub 2024 Mar 27.

Authors

Maria Vittoria Cossu¹, Antonio D'Avolio², Cristina Gervasoni¹, Andrea Giacomelli¹, Dario Cattaneo¹, Davide Moschese¹

Affiliations

¹ Department of Infectious Diseases, ASST Fatebenefratelli Sacco University Hospital, Milan, Italy.
² Laboratory of Clinical Pharmacology and Pharmacogenetics, Department of Medical Sciences, Amedeo di Savoia Hospital, University of Turin, Turin, Italy.

PMID: 38534104
PMCID: PMC11064637 (available on 2024-09-27)
DOI: 10.1128/aac.00175-24

No abstract available

Keywords: human immunodeficiency virus.

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Adult
Anti-HIV Agents* / administration & dosage
Anti-HIV Agents* / pharmacokinetics
Anti-HIV Agents* / therapeutic use
Diketopiperazines*
Female
HIV Infections* / drug therapy
Humans
Injections, Intramuscular
Male
Middle Aged
Pyridones* / administration & dosage
Pyridones* / pharmacokinetics
Pyridones* / therapeutic use
Rilpivirine* / administration & dosage
Rilpivirine* / pharmacokinetics
Rilpivirine* / therapeutic use

Substances

Rilpivirine
Pyridones
cabotegravir
Anti-HIV Agents
Diketopiperazines